Citicoline - a neuroprotector with proven effects on glaucomatous disease - PubMed (original) (raw)
Review
Citicoline - a neuroprotector with proven effects on glaucomatous disease
Chitu Iulia et al. Rom J Ophthalmol. 2017 Jul-Sep.
Abstract
Citicoline is the generic name of cytidine-5'-diphosphocholine (CDP-choline), an endogenous compound that is able to increase the levels of neurotransmitters in the central nervous system by interacting with the synthesis of cellular membranes phospholipids, especially phosphatidylcholine. Exogenous Citicoline, administered by ingestion or injection, is hydrolyzed and dephosphorylated in order to form cytidine and choline, which resynthesize CDP-choline inside brain cells. It has proven neuroprotective effects in Alzheimer disease, stroke, and Parkinson's disease, as well as in glaucoma and amblyopia. Citicoline acts as a neuroprotector for those patients with progressive glaucomatous disease in spite of well-controlled intraocular pressure. The purpose of this review was to outline the main features of Citicoline and the evidences of its effect in glaucoma.
Keywords: Citicoline; glaucoma; neuroprotection.
Figures
Fig. 1
Chemical structure of Citicoline
Fig. 2
The CDP-choline pathway
Fig. 3
Transverse sections in rat retina at 7 days after KA injection using H-E staining. In control retina, five, well organized retinal layers are seen (A). In the KA-injected group, the thickness of retina is markedly reduced due to loss of internal nuclear (INL) and internal plexiform layers (IPL) (B). Conserved retinal layers in KA-injected group treated with Citicoline (C)
Fig. 4
Electrophysiological examination at baseline, after 60 days of treatment with Citicoline and after the last washout period. Improvement of visual field and electrophysiological parameters after treatment followed by regression or stabilization after washout [
]
Similar articles
- Cytidine 5'-Diphosphocholine (Citicoline) in Glaucoma: Rationale of Its Use, Current Evidence and Future Perspectives.
Roberti G, Tanga L, Michelessi M, Quaranta L, Parisi V, Manni G, Oddone F. Roberti G, et al. Int J Mol Sci. 2015 Nov 30;16(12):28401-17. doi: 10.3390/ijms161226099. Int J Mol Sci. 2015. PMID: 26633368 Free PMC article. Review. - Pharmacodynamics of citicoline relevant to the treatment of glaucoma.
Grieb P, Rejdak R. Grieb P, et al. J Neurosci Res. 2002 Jan 15;67(2):143-8. doi: 10.1002/jnr.10129. J Neurosci Res. 2002. PMID: 11782957 Review. - Neuroprotective properties of citicoline: facts, doubts and unresolved issues.
Grieb P. Grieb P. CNS Drugs. 2014 Mar;28(3):185-93. doi: 10.1007/s40263-014-0144-8. CNS Drugs. 2014. PMID: 24504829 Free PMC article. Review. - Citicoline: pharmacological and clinical review, 2006 update.
Secades JJ, Lorenzo JL. Secades JJ, et al. Methods Find Exp Clin Pharmacol. 2006 Sep;28 Suppl B:1-56. Methods Find Exp Clin Pharmacol. 2006. PMID: 17171187 Review. - Citicoline and Retinal Ganglion Cells: Effects on Morphology and Function.
Parisi V, Oddone F, Ziccardi L, Roberti G, Coppola G, Manni G. Parisi V, et al. Curr Neuropharmacol. 2018;16(7):919-932. doi: 10.2174/1570159X15666170703111729. Curr Neuropharmacol. 2018. PMID: 28676014 Free PMC article. Review.
Cited by
- Preclinical evidence for the anxiolytic- and antidepressant-like effects of citicoline and imipramine in the sciatic nerve-ligated mice.
Zarrindast MR, Hajikarimloo B, Raissi-Dehkordi N, Raissi-Dehkordi N, Khakpai F. Zarrindast MR, et al. IBRO Neurosci Rep. 2024 Oct 28;17:364-371. doi: 10.1016/j.ibneur.2024.10.007. eCollection 2024 Dec. IBRO Neurosci Rep. 2024. PMID: 39524480 Free PMC article. - Glaucoma: Current and New Therapeutic Approaches.
Lee HP, Tsung TH, Tsai YC, Chen YH, Lu DW. Lee HP, et al. Biomedicines. 2024 Sep 3;12(9):2000. doi: 10.3390/biomedicines12092000. Biomedicines. 2024. PMID: 39335514 Free PMC article. Review. - Optic Nerve Neuroprotection in Glaucoma: A Narrative Review.
D'Angelo A, Vitiello L, Lixi F, Abbinante G, Coppola A, Gagliardi V, Pellegrino A, Giannaccare G. D'Angelo A, et al. J Clin Med. 2024 Apr 11;13(8):2214. doi: 10.3390/jcm13082214. J Clin Med. 2024. PMID: 38673487 Free PMC article. Review. - Advances in Therapies to Treat Neonatal Hypoxic-Ischemic Encephalopathy.
Ranjan AK, Gulati A. Ranjan AK, et al. J Clin Med. 2023 Oct 20;12(20):6653. doi: 10.3390/jcm12206653. J Clin Med. 2023. PMID: 37892791 Free PMC article. Review. - Valuable effects of lactobacillus and citicoline on steatohepatitis: role of Nrf2/HO-1 and gut microbiota.
El-Baz AM, El-Ganiny AM, Hellal D, Anwer HM, El-Aziz HAA, Tharwat IE, El-Adawy MA, Helal SEM, Mohamed MTA, Azb TM, Elshafaey HM, Shalata AA, Elmeligi SM, Abdelbary NH, El-Kott AF, Al-Saeed FA, Salem ET, El-Sokkary MMA, Shata A, Shabaan AA. El-Baz AM, et al. AMB Express. 2023 Jun 8;13(1):57. doi: 10.1186/s13568-023-01561-8. AMB Express. 2023. PMID: 37291355 Free PMC article.
References
- Secades JJ. Citicoline: Pharmacological and clinical review, 2010 update. Revista de neurologie. 2011 Mar;52(Suppl 2):S1–S62. - PubMed
- Muralikrishna Adibhatla R, Hatcher JF, Dempsey RJ. Citicoline: neuroprotective mechanisms in cerebral ischemia. Journal of Neurochemistry. 2002;80:12–23. - PubMed
- Gutiérrez-Fernández M, Rodríguez-Frutos B, Fuentes B, Vallejo-Cremades MT, Alvarez-Grech J, Expósito-Alcaide M, Díez-Tejedor E. CDP-choline treatment induces brain plasticity markers expression inexperimental animal stroke. Neurochem. Int. 2012;60:310–317. - PubMed
- Cacabelos R, Caamaño J, Gómez MJ, Fernández-Novoa L, Franco-Maside A, Alvarez XA. Therapeutic effects of CDP-choline in Alzheimer’s disease. Cognition, brain mapping, cerebrovascular hemodynamics, and immune factors. Ann. N. Y. Acad. Sci. 1996;777:399–403. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical